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S U M M A R Y
Background: The early detection and identiﬁcation of pathogens in central nervous system viral
infections associated with neurological disease increases the survival rate. However, the limitations of
current diagnostic methods contribute to a lack of proper diagnosis in 62% of patients. Therefore, a robust
method for detecting multiple viruses in a single reaction with high speciﬁcity, throughput, and speed is
required.
Methods: A multiplex PCR Mag-Array (MPMA) system was developed that integrates three strategies:
chimeric primer design, temperature switch PCR, and MagPlex-TAG techniques. The MPMA was used to
amplify 13 target viral sequences simultaneously, with plasmids containing speciﬁc viral sequences as
standard samples. To evaluate its clinical performance, 177 cerebrospinal ﬂuid (CSF) samples were
tested.
Results: The MPMA system presented high speciﬁcity and efﬁciency in detecting a control panel of
13 plasmids. Among 177 CSF samples, consistent results were achieved for 19 samples pre-tested using a
commercial kit. Viral pathogens were found in 28/138 undiagnosed samples, with herpes simplex
viruses (HSV-1 and HSV-2) being predominant. The 20 non-infectious samples revealed negative results.
Compared to sequencing methods, sensitivity for detecting HSV-1 and HSV-2 was 100% and 98.78%,
respectively, and speciﬁcity was 100% and 98.22%, respectively.
Conclusions: A robust MPMA system that can simultaneously and reliably detect 13 meningoencephali-
tis-associated viruses with high speciﬁcity, throughput, and speed has been developed.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Although the annual incidence of encephalitis and meningitis is
estimated to be 0.07 to 12.6 cases per 100 000 individuals
worldwide, severe disability has been reported in up to 56% of
survivors and mortality rates range between 7% and 18%.1–3 Early
identiﬁcation of the causative viral pathogen is important in order
to develop an effective treatment plan before the disease* Corresponding author. Tel.: +86 2984775368.
** Corresponding author. Tel.: +86 1058900810.
E-mail addresses: maxj@ivdc.chinacdc.cn (X. Ma), zhaogang@fmmu.edu.cn
(G. Zhao).
1 Xiaodan Shi and Rui Wu contributed equally to this study.
http://dx.doi.org/10.1016/j.ijid.2016.05.023
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).progresses to a life-threatening stage for which few curative
methods are available.4 The common viral pathogens causing
central nervous system (CNS) infections are human enterovirus
(HEV), herpes simplex virus type 1 (HSV-1), herpes simplex virus
type 2 (HSV-2), cytomegalovirus (CMV), varicella zoster virus
(VZV), and Epstein–Barr virus (EBV). Mumps virus (MuV) and
measles virus (MeV) are undergoing a worldwide resurgence.5,6
Among HEV, subtypes such as coxsackie A virus type 16 (CA16),
enterovirus type 71 (EV71), and echoviruses (ECHO) are frequently
found to be involved in CNS infection worldwide.7,8 In addition to
these, JC virus (JCV) is a major viral cause of progressive multifocal
leukoencephalopathy that is rarely included in routine detection
systems,9 and Japanese encephalitis virus (JEV) is a major cause of
viral encephalitis in geographical areas such as Asia and the
Western Paciﬁc.10ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
X. Shi et al. / International Journal of Infectious Diseases 49 (2016) 80–86 81Traditional identiﬁcation techniques such as pathogen culture
and antigen or antibody detection have limited capacity in their
clinical application, owing to low sensitivity and speciﬁcity and
high time requirements.11,12 Advanced molecular tools have aided
the development of commercial products that offer much-
enhanced sensitivity and diagnostic turnaround times.1 However,
these products have been designed to target only a few virus types,
greatly limiting their clinical application. Additionally, despite
improvements in sensitivity over previous methods, large volumes
of cerebrospinal ﬂuid (CSF) are still required by currently available
commercial products, which can be quite challenging for the
patient due to the side effects of lumbar puncture. Therefore, there
is an urgent need for a highly sensitive, highly speciﬁc, and high-
throughput pathogen detection method.
The Luminex-200 MagPlex-TAG beads array system (Luminex
Corp., Austin, TX, USA) is capable of simultaneously detecting
100 different PCR products and is thus ideal for high-throughput
screening.13 For example, the Luminex-200 xTAG respiratory
pathogen panel can simultaneously detect 14 selected viruses
involved in respiratory viral infections.14 Unfortunately, similar
products are not yet available for the detection of multiple viruses
associated with CNS infection diseases.Table 1
Primers and probesa
Name Sequence (50!30) 
HSV-1-F AGGTGACACTATAGAATATTTGATTTAAGAGTGTTGAATGTATGAAGCGCGAA
HSV-1-R GTACGACTCACTATAGGGAGGTGGGCGTGGCACTATC 
HSV-1-P TTTGATTTAAGAGTGTTGAATGTA
HSV-2-F AGGTGACACTATAGAATATATTAGAGTTTGAGAATAAGTAGTTATCGGAGGCC
HSV-2-R GTACGACTCACTATAGGGAGCCGATCCGTCCTTGTTTTC 
HSV-2-P TATTAGAGTTTGAGAATAAGTAGT
VZV-F AGGTGACACTATAGAATATTGTGTAGTTAAGAGTTGTTTAATGCAGGGAATTG
VZV-R GTACGACTCACTATAGGGAACTTGGTCGGATAGGGTGGT 
VZV-P TTGTGTAGTTAAGAGTTGTTTAAT
CMV-F AGGTGACACTATAGAATAGATAGATTTAGAATGAATTAAGTGTCTACTACACG
CMV-R GTACGACTCACTATAGGGAACACCTTGACGTACTGGTCAC 
CMV-P GATAGATTTAGAATGAATTAAGTG
EBV-F AGGTGACACTATAGAATAGTGTTATAGAAGTTAAATGTTAAGTTCGTTGCCCA
EBV-R GTACGACTCACTATAGGGAGGTTTTGCGGAGACAAGCAG 
EBV-P GTGTTATAGAAGTTAAATGTTAAG
MeV-F AGGTGACACTATAGAATAGTTTGTTGAAAGTGTAAAGTATATTCAGCAACTGC
MeV-R GTACGACTCACTATAGGGACTATCACTGGGTCATCCGTCG 
MeV-P GTTTGTTGAAAGTGTAAAGTATAT
MuV-F AGGTGACACTATAGAATATAGATTAGTTGATAAGTGTGTAATTCGGAGAACAA
MuV-R GTACGACTCACTATAGGGACTAGGACTGTACCGACTCCCA 
MuV-P TAGATTAGTTGATAAGTGTGTAAT
JCV-F AGGTGACACTATAGAATAAGAGAGTTTGTGTATATGTATAAATCCATGTCCAG
JCV-R GTACGACTCACTATAGGGAGCCATTCATGAGAGGATTGTGC 
JCV-P AGAGAGTTTGTGTATATGTATAAA
JEV-F AGGTGACACTATAGAATATTAAGAAGAATTGTATATGAGAGTTCATGGCAGTG
JEV-R GTACGACTCACTATAGGGATTTCACATCCAGCCTCCGAC 
JEV-P TTAAGAAGAATTGTATATGAGAGT
ECHO-F AGGTGACACTATAGAATAAGAGAGTTTGTGTATATGTATAAACCCTAAAAGTT
ECHO-R GTACGACTCACTATAGGGAATTACCCTCCGTCCAGAATACG 
ECHO-P AGAGAGTTTGTGTATATGTATAAA
EV71-F AGGTGACACTATAGAATATAGATTAGTTGATAAGTGTGTAATGAGCCCTCACA
EV71-R GTACGACTCACTATAGGGACGCAGCTCGTCCTTGACAT 
EV71-P TAGATTAGTTGATAAGTGTGTAAT
CA16-F AGGTGACACTATAGAATAGTTTGTTGAAAGTGTAAAGTATATCCAGCCTGATA
CA16-R GTACGACTCACTATAGGGACACAGTCACCAGGTTCCGAG 
CA16-P TAGATTAGTTGATAAGTGTGTAAT
HEV-F AGGTGACACTATAGAATATTAAGAAGAATTGTATATGAGAGTCGGTACCTTTG
HEV-R GTACGACTCACTATAGGGATTAGGATTAGCCGCATTCAG 
HEV-P TTAAGAAGAATTGTATATGAGAGT
Universal F AGGTGACACTATAGAATA 
Universal R Biotin-GTACGACTCACTATAGGGA 
HSV, herpes simplex virus; VZV, varicella zoster virus; CMV, cytomegalovirus; EB, Epste
encephalitis virus; ECHO, echovirus; EV71, enterovirus 71; CA16, coxsackie A virus typ
a Primers used in the multiplex PCR for detection: the chimeric primer was composed
anti-TAG region shown in red, and a speciﬁc region shown in standard text.
b Reference genes were from the reference study by Venter et al.15.In this study, a multiplex PCR Mag-array (MPMA) system was
developed, based on the Luminex-200 system in combination with
MagPlex-TAG technology (xTAG); this system detects 13 viruses
simultaneously: HSV-1, HSV-2, CMV, VZV, EBV, MuV, MeV, JCV,
JEV, CA16, EV71, ECHO, and HEV.
2. Materials and methods
2.1. Plasmids and CSF samples
Fragments of the speciﬁc genes from 13 selected viruses (HSV-
1, HSV-2, CMV, VZV, EBV, MuV, MeV, JCV, JEV, CA16, EV71, ECHO,
and HEV) were synthesized by Sangon Biotech (Shanghai, China)
(Table 1) and subcloned into the pcDNA3.1 plasmid (Thermo Fisher
Scientiﬁc, Waltham, MA, USA).15 Each recombinant pcDNA3.1
plasmid was used as a standard plasmid for subsequent experi-
ments. A blank pcDNA3.1 plasmid was used as a vehicle plasmid
control (VPC).
To further conﬁrm the feasibility of the MPMA system, 177 CSF
specimens were collected (138 undiagnosed specimens from
patients with meningoencephalitis symptoms, 19 samples pre-
tested using commercial kits, and 20 specimens from patientsGene target Conc. (nM) Tm GC% Length
CTGACGA 81Lb 120 59.67 55.56 189
120 60.51 66.67
CTTTGTTGC UL23b 40 60.39 55 163
40 59.55 55
GAGCGGTT QCMDb 120 60.68 57.89 222
120 60.25 55
TCAGCGTTCG UL83b 160 59.87 52.38 202
160 59.93 52.38
CAGTCAGG LMP-2Ab 120 60.23 57.89 165
120 60.04 55
ATGGTAGCTT KJ36545 120 60.27 47.62 250
120 60 57.14
GCCAGATACC KF481689 100 59.52 52.38 202
100 60.06 57.14
AGTCTTCTGC argno 120 59.45 52.38 202
120 59.97 50
TCCTACGTG GP1 120 59.75 55 183
120 60.04 55
ATGAGGATTTCGCA VP1b 120 59.41 40 131
120 59.37 40
CACGCTCTAC VP1b 100 60.9 60 152
100 60.45 57.89
TTTGTCGAAGC TW-3126-98 polyprotein 90 59.71 50 157
90 60.32 60
TGCGCCTGT 50 UTRb 100 60.23 58
100 59.36 52 474
1000
3000
in–Barr virus; MeV, measles virus; MuV, mumps virus; JCV, JC virus; JEV, Japanese
e 16; HEV, human enterovirus; UTR, untranslated region.
 of three regions, including a universal primer F/R region indicated in bold font, an
Table 2
Results of parallel testinga
No. MPMA system Blinded test
1 ECHO & HEV HEV
2 HSV-1 HSV-1
3 EV71 & HEV HEV
4 VZV VZV
5 CMV CMV
6 EB EB
7 EB EB
8 CA16 & HEV HEV
9 HSV-1 HSV-1
10 ECHO & HEV HEV
11 HSV-1 HSV-1
12 HSV-2 HSV-2
13 HSV-2 HSV-2
14 Negative HHV6
15 Negative HHV6
16 Negative Negative
17 Negative Negative
18 Negative Negative
19 Negative Negative
ECHO, echovirus; HEV, human enterovirus; HSV, herpes simplex virus; EV71,
enterovirus 71 [Au?8]; VZV, varicella zoster virus; CMV, cytomegalovirus; EB,
Epstein–Barr virus; CA16, coxsackie A virus type 16; HHV, human herpesvirus.
a Clinical specimens testing positive in parallel using commercial kits at the
Center Laboratory of the Beijing Institute of Pediatrics and upon screening with the
MPMA system. &: ECHO, EV71, and CA16 are types of HEV. The MPMA system
includes both the standard HEV primers and the primers for some common
enteroviruses such as ECHO, EV71, and CA16.
X. Shi et al. / International Journal of Infectious Diseases 49 (2016) 80–8682without any of the viral infections). The 138 undiagnosed patients
were required to present one or more of the following symptoms:
headache, photophobia, nausea/vomiting, meningeal signs, cranial
nerve injuries, altered mental status, seizures, and lethargy/fever.
The 19 clinical CSF specimens had been tested previously using the
Seeplex Meningitis ACE Detection Kit (Seegene Inc., Seoul, Korea)
in the Center Laboratory of the Capital Institute of Pediatrics. The
testing results are shown in Table 2. Re-evaluation of the
specimens using the method developed in this study permitted
direct comparison between the methods. The 20 control CSF
specimens were negative for any viral infection and were obtained
from patients who also presented one or all of the following: stroke
(n = 13), cognitive impairment (n = 3), vertigo syndrome (n = 2), or
papilledema (n = 2).
2.2. DNA/RNA extraction
DNA plasmids were extracted using an E.Z.N.A. Plasmid Mini Kit
I (Omega Bio-tek, Norcross, GA, USA), eluted in 50 ml elution buffer,
and stored at 20 8C. The DNA and RNA from the clinical samples
were extracted directly from 200 ml CSF sample using a QIAamp
MinElute Virus Spin Kit (Qiagen, Venlo, Netherlands) according to
the manufacturer’s instruction. DNA and RNA were each eluted in
35 ml elution buffer (Qiagen) and stored at 20 8C.
2.3. Primers and probes
Primers and probes (Table 1), optimized to target an amplicon
in the range of 150–220 bp for virus detection, were designed using
the National Center for Biotechnology Information (NCBI) Primer
Basic Local Alignment Search Tool (BLAST) program and synthe-
sized by Sangon Biotech (Shanghai, China). The chimeric primer
strategy was introduced into this PCR system. Each chimeric
primer was composed of two or three regions, including a universal
primer F/R region, a present or absent anti-TAG region, and a
speciﬁc region (Table 1). A pair of universal primers was adopted to
facilitate unbiased ampliﬁcation in the MPMA system. The
efﬁciency of this pair of universal primers has been demonstrated
in previous studies.16–19 The R universal primers were biotinylatedat their 50 end. The anti-TAG sequences included in the chimeric
primers were selected with assistance from the Luminex technical
support department. The primers were dissolved in sterile ddH2O
with a ﬁnal concentration of 10 mM and stored individually at
20 8C.
2.4. Multiplex PCR Mag-array system procedure and assay analysis
The multiplex PCR Mag-array system (MPMA system) com-
bined multiplex PCR ampliﬁcation and MagPlex-TAG hybridization
techniques. The reverse transcription reaction was performed
using a PrimeScript RT-PCR Kit (TaKaRa, Osaka, Japan) in a total
volume of 20 ml containing the following components: 4 ml
template, 4 ml 5  PrimeScript RT Master Mix, 2 ml ddH2O, and
8 ml random primers. The reaction conditions were programmed
as follows: 37 8C for 15 min, 85 8C for 5 s, and 4 8C on hold. The
multiplex PCR ampliﬁcation was performed in a total volume of
25 ml containing the following components: 6 ml template, 40–
120 nM each primer (optimized concentrations of each primer are
shown in Table 1), and 12.5 ml multiplex master mix (Qiagen,
Ballerup, Denmark). The PCR cycles for temperature switched PCR
(TSP), which is a key point for speciﬁcity, have been published
previously,18 and were programmed as follows: 95 8C for 15 min;
10 cycles at 95 8C for 30 s, 60 8C for 45 s, 72 8C for 40 s; 5 cycles at
95 8C for 30 s, 68 8C for 45 s, 72 8C for 60 s; 30 cycles at 95 8C for
30 s, 53 8C for 45 s, 72 8C for 60 s; and a ﬁnal step at 72 8C for 10 min
to complete all reactions before maintenance at 4 8C.
MagPlex-TAG hybridization contains the key component of the
Mag-array system, MagPlex-TAG Microspheres (Luminex), which
are color-coded oligonucleotide-coupled polystyrene microparti-
cles. As illustrated in Figure 1, the attached 24-base DNA sequence
called an ‘anti-TAG’ allows the quick detection of genes of interest
by simply adding a complementary ‘TAG’ sequence to the primers
and probes. In brief, in each well of a 96-well ﬁlter plate
(MultiScreen Filter Plates; Merck Millipore, Billerica, MA, USA),
10 ml multiplex PCR product was added to 40 ml microsphere mix
containing 1500 beads in each MagPlex-TAG set in
1  hybridization buffer (0.2 M NaCl/0.1 M Tris/0.08% Triton X-
100, pH 8.0). The hybridization mixture was incubated at 96 8C for
2 min, followed by 37 8C incubation for 30 min. Hybridization
buffer (50 ml) containing 2 mg/ml streptavidin–R-phycoerythrin
(Thermo Fisher) was added to each well, followed by incubation in
the dark at 37 8C for 15 min with constant shaking at 500 rpm. At
the end of the incubation, the plate was washed with fresh
1  hybridization buffer twice, followed by the addition of fresh
beads with shaking at 500 rpm for 5 min. At the end of the
incubation, the plate was loaded into the Luminex-200 instrument
for further detection.
Fluorescence signals were recorded as the median ﬂuorescence
intensity (MFI)20 and the data were analyzed using Luminex-200
Bioplex v.5.0. All data were displayed as the mean  standard error
of the mean (SEM). Positive (MFI) = 3  [MFI (VPC)  MFI (back-
ground)].21,22
2.5. Speciﬁcity evaluation and limits of detection (LOD)
To evaluate the speciﬁcity of the detection, all samples
examined with the MPMA system were further validated by
performing monoplex PCR and sequencing. PCR products were
further puriﬁed using a PCR puriﬁcation kit (SolGent; Solgent Co.,
Ltd, Daejeon, Korea) prior to sequencing at the Beijing Genomics
Institute (China). Sequencing data were subsequently analyzed
using NCBI BLAST (http://www.ncbi.nlm.nih.gov/BLAST). In a
parallel experiment, DNA and RNA isolated from 19 CSF samples
were screened in a blinded manner by the Center Laboratory of the
Capital Institute of Pediatrics.
Figure 1. Outline of the chimeric primer design. (A) Structure of the chimeric primer: the upstream primer includes a speciﬁc region, the anti-TAG region, and the universal
region; the downstream primer includes a speciﬁc region and a universal region; and the two primers, the universal primer F and the universal primer R, are biotinylated and
effect universal ampliﬁcation. (B) Products of the TSP PCR. (C) The TAG allows hybridization to MagPlex-TAG microspheres with a competing anti-TAG complementary strand
generated in the PCR reaction.
X. Shi et al. / International Journal of Infectious Diseases 49 (2016) 80–86 83To evaluate the LODs of the MPMA system, a panel of 13 control
plasmids, each containing sequence of the target gene of each
speciﬁc virus, was prepared with plasmid dilutions from 106 to 102,
50, and 10 copies. The plasmid DNAs were extracted with an
E.Z.N.A Plasmid Mini Kit. The DNA copy number was determined
with a biophotometer (Eppendorf, Hamburg, Germany). Each
sample was tested 15 times and the results were analyzed by
probit estimation using SPSS version 17.0 software (SPSS Inc.,
Chicago, IL, USA).
2.6. ELISA
All 138 specimens were processed in the Department of Clinical
Laboratory in the study hospital, and the speciﬁc types of
pathogens each specimen might carry were identiﬁed using
commercial ELISA kits (Beier, China, Shanghai) designed using
antibodies customized to target individual viruses, including the
EBV, HSV-1, and HSV-2 viral capsids.
3. Results
3.1. Determination of the LOD of plasmid samples
The MPMA assay developed in this study identiﬁed the viral
types of all 13 standard plasmids with high speciﬁcity (Table 3). In
addition, the VPC showed no positive results during the reactions.
No signiﬁcant primer or probe homology was observed with
unrelated sequences. The results were also consistent with the
data obtained by monoplex PCR, further strengthening the
conclusion that the MPMA system provides high speciﬁcity.
Sequencing analysis conﬁrmed that the primers speciﬁcally
ampliﬁed the plasmid controls for each of the 13 targets.
The 95% LODs for the speciﬁc primers in the assay were
evaluated individually in a multiplex format. The LODs were 103
copies/reaction for EBV, HSV-2, VZV, and MuV; 102 copies/reaction
for HSV-1, CMV, MeV, and JCV; 50 copies/reaction for JEV; and 50,
100, 100, and 100 copies/reaction for HEV, CA16, EV71, and ECHO,
respectively.3.2. Sensitivity and speciﬁcity of the MPMA system for clinical
specimens
Blinded testing revealed 13 positive results from the 15 pre-
tested positive samples containing HSV-1, HSV-2, CMV, VZV, EBV,
and HEV. Two human herpesvirus 6 (HHV 6) samples, which were
not detected using the MPMA system, showed negative results. In
addition, four pre-tested negative samples were veriﬁed by the
MPMA system to also yield negative results (Table 2).
The positive rate of MPMA detection for all 177 CSF specimens
was validated by comparison to sequencing and ELISA detection
results. The positive rates determined based on the data obtained
by the MPMA system alone were 7.9% (14/177) for HSV-1, 6.21%
(11/177) for HSV-2, 2.25% (4/177) for EBV and ECHO, 1.12% (2/177)
for CMV and VZV, and 0.56% (1/177) for MeV, CA16, EV71, and HEV.
The conﬁrmed positive rates by sequencing were 6.77% (12/177)
for HSV-1, 4.5% (8/177) for HSV-2, 1.69% (3/177) for ECHO and EBV,
and 0.5% (1/177) for MeV, CMV, VZV, CA16, EV71, and HEV. The
HEV-positive samples were found to represent enterovirus type
68 infection. The positive rates by ELISA were 7.9% (14/177) for
HSV-1, 5.6% (10/177) for HSV-2, and 2.8% (5/177) for EBV.
The overall concordance between the MPMA system and DNA
sequencing was 96.05% (170/177). Evaluation of the positive rate of
the MPMA system (Table 4) using DNA sequencing as the gold
standard yielded 100% sensitivity and 98.78% speciﬁcity for HSV-1,
100% and 98.22% for HSV-2, and 100% and 99.43% for CMV, VZV, and
EB, respectively. However, when compared to ELISA results, the
sensitivity of the MPMA system decreased to 14.2% for HSV-1, 30%
for HSV-2, and only 20% for EB. The kappa values of consistency
between the MPMA system and sequencing and between the
MPMA system and ELISA detection are shown in Table 4.
4. Discussion
In this study, an MPMA system was developed that combines
multiplex PCR and MagPlex-TAG techniques with the MPMA
system. The results obtained from 13 positive control plasmids,
19 pre-tested samples, and 158 clinically undiagnosed samples
revealed high sensitivity and speciﬁcity.
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chimeric primer design and TSP strategy were introduced to
minimize unbiased ampliﬁcation and the formation of primer
dimers. A chimeric primer was designed to target sequences in
three individual regions from the 50 to 30 end, including a universal
region, an anti-TAG region, and a sequence-speciﬁc region. The
universal primer was a quasi-T7 sequence and was selected as a
default sequence calculated by GeXP eXpress Proﬁler softwar-
e.16,18,19 Sequences selected within the anti-TAG region were used
as probes for hybridization. PCR ampliﬁcation products contain a
TAG that is complementary to the anti-TAG that is bound with the
Mag-beads supplied by Luminex (Figure 1). Notably, although
variation of the targeted viral DNA sequences might result in a
false-negative result, this factor was not included in the speciﬁc
primer design. However, the results demonstrated that the
chimeric primer design and the TSP strategy were sufﬁcient to
detect multiple pathogen genes present in several clinical speci-
mens, as has been shown in previous reports by the present study
group.16,18,19,23 The 50 end of the universal R sequence was
biotinylated, a strategy with an economical advantage compared
to other methods such as the xTAG assay in which all 50 ends of the
antisense-primers are biotinylated.24,25
Another major challenge of all prior detection methods is a high
background noise-to-signal ratio due to the low volume of clinical
samples available, including for CSF samples.26 To minimize
background noise, precautions must be taken to prevent contami-
nation, such as by including a wash step in the MPMA system. The
hybridization products were loaded into a 96-well ﬁlter plate and
washed twice with 1  hybridization buffer. The background
signals for all bead sets in the no-template controls and the
background from wells that only contained beads and hybridiza-
tion buffer were as low as <100 MFI. After the washing procedure,
the MFI value of the hybridized biotinylated product was not
substantially changed.
There were two primary reasons for the introduction of MuV,
MeV, JCV, and JEV into this new MPMA system, resulting from
geographic considerations. Firstly, in developed countries where
vaccines are prevalent, meningoencephalitis caused by MuV, MeV,
or JCV has almost disappeared,5,6 whereas irregular use of vaccines
in developing countries has led to a 1–2% incidence of meningo-
encephalitis caused by MuV, MeV, and JCV in these areas.27,28 One
MuV-positive sample was found using the new MPMA system,
which was conﬁrmed by sequencing. Secondly, arboviruses such as
JEV are only prevalent in East Asia and the Western Paciﬁc. Thus,
MuV, MeV, JCV, and JEV were included in the MPMA system to
facilitate detection in these areas.
The identiﬁcation of viral pathogens from 13 standard plasmids
and 19 pre-tested clinical specimens suggested that the MPMA
system offers high speciﬁcity and sensitivity. No cross-reactions
were detected between the 13 targets genes. Among the
19 samples, four HEV samples tested positive for two ECHO and
HEV viruses alone, one sample was positive for EV71 and HEV
viruses, and one sample was positive for CA16 and HEV viruses, as
conﬁrmed by the sequencing results.
The detection results for the 177 clinical specimens showed
overall high concordance between the MPMA system and DNA
sequencing (96.05%). However, comparison of the results of the
MPMA system with the ELISA assay resulted in a substantial
decrease in the positive rate for HSV-1 (14.2%), HSV-2 (30%), and EB
(20%). The kappa value indicated that the MPMA system and the
ELISA kit had poor consistency. However, instead of concluding
that the new MPMA system failed to provide accurate and
consistent results, it is believed that the main reason for this
discordance is systematic inconsistency of the ELISA assay alone.
According to the ELISA assay results, 14, 10, and 5 samples tested
positive for HSV-1, HSV-2, and EBV, respectively. These samples
Table 4
Sensitivity and speciﬁcity of the MPMA assay for 177 CSF specimensa
Pathogen MPMA system positive MPMA system negative Sensitivity Speciﬁcity Kappa
Referenceb positive Referenceb negative Referenceb positive Referenceb negative
HSV-1 12 2 0 163 100% 98.78% 0.9193
HSV-2 8 3 0 166 100% 98.22% 0.8334
CMV 1 1 0 175 100% 99.43% 0.6642
VZV 1 1 0 175 100% 99.43% 0.6642
EB 3 1 0 173 100% 99.42% 0.8548
MeV 0 0 0 177
MuV 1 0 0 176 100% 100%
JCV 0 0 0 177
JEV 0 0 0 177
EV71 1 0 0 176 100% 100%
CA16 1 0 0 176 100% 100%
ECHO 3 1 0 173 100% 99.42% 0.8356
HEV 1 0 0 176 100% 100%
MPMA system positive MPMA system negative Sensitivity Speciﬁcity Kappa
ELISA positive ELISA negative ELISA positive ELISA negative
HSV-1 2 12 12 151 14.2% 93.63% 0.4572
HSV-2 3 8 7 159 30% 95.21% 0.2408
EB 1 3 4 169 20% 98.26% 0.0265
MPMA, multiplex PCR Mag-array; CSF, cerebrospinal ﬂuid; HSV, herpes simplex virus; CMV, cytomegalovirus; VZV, varicella zoster virus; EB, Epstein–Barr virus; MeV,
measles virus; MuV, mumps virus; JCV, JC virus; JEV, Japanese encephalitis virus; EV71, enterovirus 71 [Au?8]; CA16, coxsackie A virus type 16; ECHO, echovirus; HEV, human
enterovirus.
a Numbers of positive and negative specimens detected by the MPMA system are indicated as ‘MPMA system positive’ and ‘MPMA system negative’, respectively. Numbers
of positive and negative specimens detected by the reference assay are indicated as ‘reference positive’ and ‘reference negative’, respectively.
b The deﬁnition of ‘reference results’ is as described in the clinical samples, wherein 19 viruses were identiﬁed using a commercial PCR kit and the sequencing results were
reported.
X. Shi et al. / International Journal of Infectious Diseases 49 (2016) 80–86 85were collected from patients treated with antibiotics for over
1 month, whereas the remaining 10 patients were either not
exposed to any antibiotic treatment or the exposure time was less
than 1 week. Long-term antibiotic treatment might decrease the
sensitivity of molecular analysis and result in unsuccessful
bacterial and viral culture.29
The statistics from recent studies indicate that up to 57% of viral
CNS infections can be attributed to human enteroviruses.30 In the
present study, only three out of 138 patients who were suspected
to be HEV-positive were conﬁrmed to be HEV-positive with the
new system. The low percentage of enterovirus-positive patients
might be due to the relatively small sample size. In addition, most
cases of enteroviruses encephalitis occur in children,31 whereas in
this study, only seven of the 138 suspected clinical samples were
from children under the age of 14 years.
The 13 targets assessed in this study cover 90% of the known
viral pathogens that are leading causes of CNS infection in
developing countries,31,32 which likely underlies the ﬁnding that
the positive rate was markedly increased compared to the
previously obtained rate (3.8%) using routine PCR techniques.33
However, the positive rate (23.16%) was lower than expected,
suggesting that there might be other factors yet to be identiﬁed
that are required for optimized detection. The size of the cohort has
been expanded for a follow-up study, to avoid statistical deviation.
In conclusion, in this study, an MPMA system was developed
with high speciﬁcity to detect 13 viruses involved in CNS infection.
This system was demonstrated to function as an additional
detection tool that could compensate for the disadvantages of
currently popular methods by providing high speciﬁcity, high
throughput, and rapid detection. Additionally, this system might
also be used for pathogen screening and routine surveillance of
CNS infection.
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